First American Bank Buys 1,991 Shares of AbbVie Inc. $ABBV

First American Bank lifted its position in AbbVie Inc. (NYSE:ABBV) by 1.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 119,936 shares of the company’s stock after buying an additional 1,991 shares during the period. AbbVie comprises 1.6% of First American Bank’s portfolio, making the stock its 12th largest holding. First American Bank’s holdings in AbbVie were worth $26,085,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the 3rd quarter valued at about $26,000. Litman Gregory Wealth Management LLC bought a new position in AbbVie during the fourth quarter valued at approximately $28,000. Imprint Wealth LLC boosted its holdings in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Westend Capital Management LLC bought a new stake in AbbVie in the 4th quarter worth approximately $29,000. Finally, IFC & Insurance Marketing Inc. bought a new stake in AbbVie in the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 3.4%

NYSE ABBV opened at $251.52 on Friday. AbbVie Inc. has a 12 month low of $181.73 and a 12 month high of $253.35. The stock has a market cap of $444.38 billion, a price-to-earnings ratio of 123.90, a PEG ratio of 0.74 and a beta of 0.32. The company’s 50 day moving average is $215.16 and its two-hundred day moving average is $219.18.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the previous year, the business earned $2.46 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. Sell-side analysts forecast that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

Analyst Ratings Changes

ABBV has been the subject of several research analyst reports. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Thursday, April 30th. Cantor Fitzgerald restated an “overweight” rating on shares of AbbVie in a research note on Tuesday. Evercore set a $235.00 price target on shares of AbbVie in a research report on Friday, May 15th. Canaccord Genuity Group increased their price objective on shares of AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.